SCHEMBL8042944

SCHEMBL8042944

Cc1ccc(-c2oc3cc(O)cc(O)c3c(=O)c2O)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ABCB1 P08183 8/20 0.81
CYP1A2 P05177 8/20 0.81
MEN1 O00255 8/20 0.81
KMT2A Q03164 8/20 0.81
CYP1A1 P04798 7/20 0.81
CYP1B1 Q16678 7/20 0.81
FTO Q9C0B1 6/20 0.81
CYP3A4 P08684 6/20 0.81
CYP2C9 P11712 6/20 0.81
XDH P47989 6/20 0.81
MAPT P10636 5/20 0.81
KDM4E B2RXH2 5/20 0.81
ALOX15 P16050 5/20 0.81
HSD17B10 Q99714 5/20 0.81
APP P05067 5/20 0.81
BCHE P06276 4/20 0.81
CYP2D6 P10635 4/20 0.81
ACHE P22303 4/20 0.81
CYP2C19 P33261 4/20 0.81
CA12 O43570 4/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23919099 0.90 MEN1 (0.65) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL18817 0.90 MEN1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL1259228 0.90 MEN1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL29378805 0.90 MEN1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL30655455 0.90 MEN1 (1.00) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL38651062 0.88 MEN1 (0.97) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL31749037 0.88 MEN1 (0.97) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL34461912 0.88 MEN1 (0.97) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL31256029 0.88 MEN1 (0.97) ABCB1CYP1A2MEN1KMT2ACYP1A1
Kaempferol SCHEMBL31577746 0.88 MEN1 (0.97) ABCB1CYP1A2MEN1KMT2ACYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230346737-A1 COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF VIRUS INFECTIONS Arjil Biotech Holding Company Limited (TW) 2023-11-02 US disclosed
US-20230200388-A1 COMPOUNDS AND METHODS FOR STIMULATING PLANTS Sound Agriculture Company (US) 2023-06-29 US disclosed
EP-3007713-B1 OILY EXTRACT OF PLANTS OF RUBUS SPECIES AND USES THEREOF IN MEDICAL AND COSMETIC FIELDS MEDICINA VEGETALE TRADIZIONALE GROUP S R L (IT) 2019-10-23 EP disclosed
US-9295664-B2 Methods for lowering blood glucose UNIVERSITY OF IOWA RESEARCH FOUNDATION (US) 2016-03-29 US disclosed
US-8865779-B2 Compounds, compositions, and methods for reducing or eliminating bitter taste CHROMOCELL CORPORATION (US) 2014-10-21 US disclosed
US-20140147537-A1 FRUIT EXTRACTS PROVEXIS NATURAL PRODUCTS LIMITED (GB) 2014-05-29 US disclosed
US-8426568-B2 Rhamnose substituents of SL0101 and therapeutic uses thereof UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2013-04-23 US disclosed
US-20110206794-A1 FRUIT EXTRACTS PROVEXIS NATURAL PRODUCTS LIMITED (GB) 2011-08-25 US disclosed
US-20110190514-A1 PYRONE ANALOG COMPOSITIONS AND METHODS LIMERICK BIOPHARMA, INC. (US) 2011-08-04 US disclosed
US-7947733-B2 Phosphorylated pyrone analogs and methods LIMERICK BIOPHARMA (US) 2011-05-24 US disclosed
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT LIMERICK BIOPHARMA, INC. (US) 2010-11-25 US disclosed
US-20100204089-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. 2010-08-12 US disclosed
US-20100189653-A1 Pyrone analogs for therapeutic treatment LIMERICK BIOPHARMA, INC. 2010-07-29 US disclosed
US-20100144612-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. 2010-06-10 US disclosed
US-20100016245-A1 RHAMNOSE SUBSTITUENTS OF SL0101 AND THERAPEUTIC USES THEREOF UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) 2010-01-21 US disclosed
US-20090325906-A1 Methods and compositions for therapeutic treatment LIMERICK BIOPHARMA, INC. 2009-12-31 US disclosed
US-20090258939-A1 PYRONE ANALOG COMPOSITIONS AND METHODS LIMERICK BIOPHARMA, INC. 2009-10-15 US disclosed
US-20090082400-A1 SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS LIMERICK BIOPHARMA, INC. 2009-03-26 US disclosed
US-20090069273-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS LIMERICK BIOPHARMA, INC. 2009-03-12 US disclosed
US-20080152735-A1 Herbal Extract Having Anti- Influenza Virus Activity and Preparation of Same NATIONAL DEFENSE MEDICAL CENTER (TW) 2008-06-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016245-A1 RHAMNOSE SUBSTITUENTS OF SL0101 AND THERAPEUTIC USES THEREOF SPHK1, SGPL1, SRPK1 ABCB1 1704/4885CYP1A2 3347/4885MEN1 3169/4885
US-20090069273-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS PCK1, PC, PCK2 ABCB1 29/4885CYP1A2 832/4885MEN1 4072/4885
US-20110206794-A1 FRUIT EXTRACTS F3, NEU3, GP6 ABCB1 762/4885CYP1A2 2231/4885MEN1 4543/4885
US-20090258939-A1 PYRONE ANALOG COMPOSITIONS AND METHODS CYP11B2, CYP11B1, GLS2 ABCB1 1830/4885CYP1A2 817/4885MEN1 535/4885
US-20090325906-A1 Methods and compositions for therapeutic treatment SLC2A1, SLC2A2, SLC2A3 ABCB1 252/4885CYP1A2 3381/4885MEN1 4409/4885
US-20230200388-A1 COMPOUNDS AND METHODS FOR STIMULATING PLANTS SNRK, GRK1, PPIP5K2 ABCB1 4561/4885CYP1A2 4273/4885MEN1 3498/4885
US-20100297020-A1 PHOSPHORYLATED AND PHOSPHONATED PYRONE ANALOGS FOR THERAPEUTIC TREATMENT PC, PCK1, PYGL ABCB1 1417/4885CYP1A2 2311/4885MEN1 2302/4885
US-20140147537-A1 FRUIT EXTRACTS F3, NEU3, GP6 ABCB1 672/4885CYP1A2 2204/4885MEN1 4467/4885
US-20100189653-A1 Pyrone analogs for therapeutic treatment PC, GLS2, CYP27A1 ABCB1 540/4885CYP1A2 614/4885MEN1 1731/4885
US-20100144612-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS PCK1, PC, PCK2 ABCB1 29/4885CYP1A2 832/4885MEN1 4072/4885
US-20100204089-A1 PHOSPHORYLATED PYRONE ANALOGS AND METHODS PCK1, PC, PCK2 ABCB1 29/4885CYP1A2 832/4885MEN1 4072/4885
US-20110190514-A1 PYRONE ANALOG COMPOSITIONS AND METHODS CYP11B2, CYP11B1, GLS2 ABCB1 1830/4885CYP1A2 817/4885MEN1 535/4885
US-20090082400-A1 SOLUBLE PYRONE ANALOGS METHODS AND COMPOSITIONS PGF, ABCG2, PYGB ABCB1 16/4885CYP1A2 97/4885MEN1 3857/4885
US-20230346737-A1 COMPOUNDS AND METHODS FOR PREVENTION AND TREATMENT OF VIRUS INFECTIONS SLC10A1, HAVCR2, ACE2 ABCB1 47/4885CYP1A2 1031/4885MEN1 2909/4885
US-20080152735-A1 Herbal Extract Having Anti- Influenza Virus Activity and Preparation of Same AGO2, MAVS, NOTUM ABCB1 1400/4885CYP1A2 814/4885MEN1 3746/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.